BRAF and non-small cell lung carcinoma: A phase II study of patients with BRAF V600E-mutant metastatic NSCLC reported a patient with concomitant METex14 skipping, who was treated by trial regimen – dabrafenib 150 mg twice daily plus trametinib 2 mg once daily orally after progression on platinum-based chemotherapy (15).